European Journal of Preventive Cardiology

Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Incident Atrial Fibrillation in Type 2 Diabetes: A Population-Based Target Trial Emulation

By Daniel A. Ostrovsky, Hilmi Alnsarsra, David Shamia, Gal Tsaban

Cohort study of 216,293 peopleInterventions

5 years

The paper

Daniel A. Ostrovsky, Hilmi Alnsarsra, David Shamia, Gal Tsaban

Ben-Gurion University of the Negev

European Journal of Preventive Cardiology, 6 Sep 2026

doi.org/10.1093/eurjpc/zwag478 PubMed 42700963

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes